Clinical trials: Metabolism and Excretion
Healthy Volunteer Study
Mass Balance Study of AT-527 in Healthy Adult Male Subjects (R07496998)
Mass balance study of AT-527 in Healthy Male Subjects.
- Trial name
- NCT05004415
- Testing
- AT-527 (R07496998)
- Where
- United States
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Atea Pharmaceuticals, Inc.
Healthy Volunteers
Copanlisib Mass Balance Study
The study aims to provide understanding of the relative relevance of the different excretion pathways of Copanlisib in humans, as well as to characterize its metabolite profile.
- Trial name
- NCT02119221
- Testing
- Copanlisib (BAY80-6946)
- Where
- Netherlands
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Bayer
Clinical Trial, Phase I, Pharmacokinetics
Rogaratinib (BAY1163877) Human Mass Balance Study
The objective of this study is to determine the mass balance and routes of excretion of total radioactivity after a single oral 200 mg dose of [14C]rogaratinib given as a solution.
- Trial name
- NCT03484585
- Testing
- Rogaratinib (BAY1163877)
- Where
- Netherlands
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Bayer
Healthy Volunteers
A Study Investigating [14C]-Labeled RO7269162 in Healthy Male Participants
This study will investigate how RO7269162 labeled with a carbon tracer ([14C]) is absorbed, metabolized, and eliminated by the body after a single dose in healthy male volunteers.
- Trial name
- NCT06733298
- Testing
- [ 14C]-labeled RO7269162
- Where
- Netherlands
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Hoffmann-La Roche
Healthy Participant Study
RE104 Radiolabeled Mass Balance (hAME) Study
The purpose of this study is to characterize the absorption, metabolism and routes of excretion of RE104 and its metabolites in healthy volunteers.
- Trial name
- NCT07146191
- Testing
- 2-[14C]-RE104 for Injection
- Where
- United States
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Reunion Neuroscience Inc
Healthy Subjects
Single Dose Study To Study The Absorption, Metabolism And Excretion Of Famitinib
The purpose of this study is to evaluate the excretion balance, metabolic profile and the routes of excretion of famitinib in healthy adult male subjects.
- Trial name
- NCT05473468
- Testing
- Famitinib
- Where
- China
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Healthy
Open-Label Absorption, Distribution, Metabolism, Excretion (ADME) and Pharmacokinetics (PK) Following a Single Oral Dose of AZD1236 in Healthy Male Subjects
The purpose of this study is to characterise the metabolism, excretion and pharmacokinetics of a single oral dose of [14C] AZD1236 in healthy male subjects.
- Trial name
- NCT01007929
- Testing
- 14C-AZD1236
- Where
- United Kingdom
- Volunteers
- 4 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Healthy Male Subjects
Phase 1, Open-label Study of the Absorption, Metabolism, and Excretion of [14C]-KW-6356
This is an open-label, single-dose study in healthy male subjects to investigate the absorption, metabolism, and excretion (AME) of KW-6356.
- Trial name
- NCT04147910
- Testing
- KW-6356
- Where
- United States
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Kyowa Kirin, Inc.
Advanced Hematologic Malignancies
How [14C]-DSP-5336 is Absorbed, Broken Down, and Removed From the Body After a Single Oral Dose in Patients With Advanced Blood Cancers
The purpose of this study is to evaluate the absorption, metabolism, and excretion of DSP-5336 following a single oral administration of the study drug in patients with hematologic malignancies whose disease has progressed after…
- Trial name
- NCT07444268
- Testing
- DSP-5336, [14C]-DSP-5336
- Where
- 2 sites in United States
- Volunteers
- 8 people
- Sponsor
- Sumitomo Pharma America, Inc.
Diffuse Large B Cell Lymphoma, Primary Mediastinal Lymphoma
Open-Label, Multi-Center, Two-Part, Ph1 Study to Characterize the PKs of an Intravenous Micro-Dose of [14C]-Tazemetostat (EPZ 6438) and the ADME of an Oral [14C]-Labeled Dose of Tazemetostat in Subjects With B-Cell Lymphomas or Adv Solid Tumors
This is a Phase 1, open-label, two-part study designed to characterize the PK of an IV dose of approximately 12 µg tazemetostat that contains approximately 500 nCi of [14C] tazemetostat and the ADME of an oral dose of 800 mg…
- Conditions
- Diffuse Large B Cell Lymphoma, Primary Mediastinal Lymphoma, Mantle-Cell Lymphoma, Follicular Lymphoma
- Trial name
- NCT03010982
- Testing
- Tazemetostat and [14C] Tazemetostat
- Where
- 2 sites in United Kingdom
- Volunteers
- 3 people
- Sponsor
- Epizyme, Inc.
Diabetes
Vitamin D and Omega-3 Trial to Prevent and Treat Diabetic Kidney Disease
The VITamin D and OmegA-3 TriaL (VITAL; NCT 01169259) is a randomized clinical trial in 20,000 U.S. men and women investigating whether taking daily dietary supplements of vitamin D3 (2000 IU) or fish oil (1 gram of omega-3 fatty…
- Trial name
- VITAL-DKD (NCT01684722)
- Testing
- Vitamin D, Omega-3 fatty acids (fish oil)
- Where
- United States
- Volunteers
- 1,312 people
- Sponsor
- University of Washington
Healthy
A Study To Understand How Radiolabelled PF-04449913 Is Taken Up By The Body, Broken Down And Then Removed From The Body
The study aims to understand, using radiolabelled PF-04449913, how this compound is modified by the body once it is absorbed. The study also aims to understand how much of the compound is broken down and how much leaves the body…
- Trial name
- NCT02110342
- Testing
- [14C] PF-04449913
- Where
- United States
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Pfizer